Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13811062 | 0.85 | USP2 (0.57) | USP2CA2CA1MEN1KMT2A | |
| SCHEMBL24672594 | 0.84 | MEN1 (0.38) | USP2CA2CA1GLP1RMEN1 | |
| SCHEMBL25921460 | 0.82 | MEN1 (0.44) | GLP1RMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL23696502 | 0.82 | MEN1 (0.46) | USP2GLP1RMEN1KMT2ATSHR | |
| SCHEMBL25697749 | 0.82 | MEN1 (0.46) | USP2GLP1RMEN1KMT2ATSHR | |
| SCHEMBL24673281 | 0.81 | GLP1R (0.46) | USP2CA2CA1GLP1RMEN1 | |
| SCHEMBL25925118 | 0.81 | USP2 (0.47) | USP2CA2CA1GLP1RMEN1 | |
| SCHEMBL22861656 | 0.80 | KMT2A (0.50) | GLP1RMEN1KMT2A | |
| SCHEMBL21106646 | 0.80 | KMT2A (0.50) | GLP1RMEN1KMT2A | |
| SCHEMBL23806825 | 0.79 | GLP1R (0.53) | GLP1RMEN1KMT2ATSHRBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885CA2 4617/4885CA1 4622/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885CA2 4617/4885CA1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.